Latest filing published 03 Mar 2026 for Aurinia Pharmaceuticals Inc., €493k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +87.9%Entry US$4.88 · Close at T+365 US$9.17
- +1.9%Entry US$10.96 · Close at T+365 US$11.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthew Maxwell Donley: trading record in brief
Filings by Matthew Maxwell Donley span 2 companies, the busiest being Aurinia Pharmaceuticals Inc. and Sucampo Pharmaceuticals, Inc. We count 30 filings; the first trade dates from 30 June 2015 and the latest from 2 March 2026.
The open-market side counts 2 purchases for €127k alongside 4 sales for €1.2M. On balance, insiders were net sellers of €1.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 24 share grants.
The record was last updated on 3 March 2026 with a share grant (€493k) in Aurinia Pharmaceuticals Inc. The clock since the last published purchase (23 November 2022) now reads 1,446 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew Maxwell Donley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 40,761 shares@ US$14.2117.6% of flowCommon StockSEC:0001600620-26-000022:1
- 58,160 shares0Common StockSEC:0001600620-26-000022:0
- 32,901 shares@ US$14.4054.7% of flowCommon StockSEC:0001636642-26-000002:0
- 42,787 shares@ US$15.9520.8% of flowCommon StockSEC:0001600620-26-000004:1
- 54,166 shares0Common StockSEC:0001600620-26-000004:0
- 135,567 shares0Common StockSEC:0001600620-25-000018:1
- 65,902 shares@ US$8.0018.1% of flowCommon StockSEC:0001600620-25-000018:2
- 58,991 shares@ US$7.9215.9% of flowCommon StockSEC:0001600620-25-000018:3
- 82,781 shares0Common StockSEC:0001600620-25-000018:0
- 40,665 shares@ US$5.5128.0% of flowCommon StockSEC:0001600620-24-000036:0
- 216,666 shares0Common StockSEC:0001600620-24-000020:0
- 271,134 sharesCommon StockSEC:0001628280-23-006532:0
- 10,000 shares@ US$4.666.1% of flowCommon StockSEC:0001628280-22-030745:0Canonical exit: 19 Feb 2023 (T+90)
- 3,052 shares@ US$12.011.2% of flowCommon StockSEC:0001628280-22-005129:1
- 8,500 shares0Common StockSEC:0001628280-22-005129:0
- 9,900 shares@ US$10.074611.2% of flowCommon StockSEC:0001628280-21-010023:0Canonical exit: 9 Aug 2021 (T+90)
- 36,975 shares@ US$18.0063.0% of flowCommon Stock, Class ASEC:0001171843-18-001107:0
- 330 shares@ US$9.100.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-18-000177:0
- 19,353 shares@ US$17.9834.1% of flowCommon Stock, Class ASEC:0001171843-18-000048:0
- 330 shares@ US$9.100.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-17-005958:0
- 336 shares@ US$8.930.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-17-004000:0
- 321 shares@ US$9.350.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-17-002918:0
- 53,000 shares0Common stockSEC:0001171843-17-001361:0
- 286 shares@ US$10.460.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-17-000123:0
- 320 shares@ US$9.380.3% of flowCommon Stock, Class A (ESPP)SEC:0001171843-16-012573:0
25 of 30 declarations
